- Products
- Reproduction
- Molecular diagnostics
- Careers
- About us
- Contacts
CISCER or Human PAX1 and JAM3 Gene Methylation Detection kit（Real-time PCR) is a test for early detection of cervical cancer based on the principle of measuring the methylation status of target genes, PAX1 and JAM3.
It is a non-invasive test where the input material is a preservative medium from a cervical smear.
The whole workflow, which takes less than 8 hours, consists of five steps: 1. cervical smear, 2. DNA extraction from the medium, 3. bisulfite conversion, 4. rt-PCR, 5. analysis of the results.
The output of the test is a "high risk" or "low risk" result, where high risk means that according to the test, the woman has been found to have cervical cancer and further testing is needed, and low risk means no cancer has been found and the woman is recommended for regular follow-up.
The manufacturer supplies a comprehensive diagnostic scheme for the management of the patient.
The test achieves the following parameters:
Sensitivity - 89% (CIN2+), 96% (CIN3+)
Specificity - 96% (CIN2+), 87% (CIN 3+)
The test is compatible with all commonly used rt-PCR instruments and is CE-IVD certified.
For more information, please contact us by e-mail: diagnostika@pentagen.cz